These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
773 related articles for article (PubMed ID: 21326202)
1. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Tan W; Zhang W; Strasner A; Grivennikov S; Cheng JQ; Hoffman RM; Karin M Nature; 2011 Feb; 470(7335):548-53. PubMed ID: 21326202 [TBL] [Abstract][Full Text] [Related]
2. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Gonzalez-Suarez E; Jacob AP; Jones J; Miller R; Roudier-Meyer MP; Erwert R; Pinkas J; Branstetter D; Dougall WC Nature; 2010 Nov; 468(7320):103-7. PubMed ID: 20881963 [TBL] [Abstract][Full Text] [Related]
3. RANKL inhibition: a promising novel strategy for breast cancer treatment. González-Suárez E Clin Transl Oncol; 2011 Apr; 13(4):222-8. PubMed ID: 21493182 [TBL] [Abstract][Full Text] [Related]
4. [Bone metastasis and RANKL]. Nakashima T Clin Calcium; 2014 Aug; 24(8):1201-8. PubMed ID: 25065872 [TBL] [Abstract][Full Text] [Related]
5. Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines. Tsubaki M; Komai M; Fujimoto S; Itoh T; Imano M; Sakamoto K; Shimaoka H; Takeda T; Ogawa N; Mashimo K; Fujiwara D; Mukai J; Sakaguchi K; Satou T; Nishida S J Exp Clin Cancer Res; 2013 Sep; 32(1):62. PubMed ID: 24011086 [TBL] [Abstract][Full Text] [Related]
6. Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas. Zoi I; Karamouzis MV; Xingi E; Sarantis P; Thomaidou D; Lembessis P; Theocharis S; Papavassiliou AG Breast Cancer Res; 2019 Dec; 21(1):132. PubMed ID: 31796128 [TBL] [Abstract][Full Text] [Related]
7. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730 [TBL] [Abstract][Full Text] [Related]
8. The RANK Pathway in Advanced Breast Cancer: Does Src Play a Role? Li R; Zhang K; Penedo TL; Kragel CP; Grizzle WE; Hameed O; Siegal GP; Wei S Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):42-50. PubMed ID: 26200837 [TBL] [Abstract][Full Text] [Related]
9. RANK-RANKL signaling pathway is critically involved in the function of CD4+CD25+ regulatory T cells in chronic colitis. Totsuka T; Kanai T; Nemoto Y; Tomita T; Okamoto R; Tsuchiya K; Nakamura T; Sakamoto N; Akiba H; Okumura K; Yagita H; Watanabe M J Immunol; 2009 May; 182(10):6079-87. PubMed ID: 19414759 [TBL] [Abstract][Full Text] [Related]
10. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Azim HA; Peccatori FA; Brohée S; Branstetter D; Loi S; Viale G; Piccart M; Dougall WC; Pruneri G; Sotiriou C Breast Cancer Res; 2015 Feb; 17():24. PubMed ID: 25849336 [TBL] [Abstract][Full Text] [Related]
11. RANKLed by the Complexity of Signaling in Breast Cancer Metastasis to the Brain. Wang K; Hackney JR; Siegal GP; Wei S Clin Breast Cancer; 2020 Oct; 20(5):e569-e575. PubMed ID: 32381383 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. Gómez-Aleza C; Nguyen B; Yoldi G; Ciscar M; Barranco A; Hernández-Jiménez E; Maetens M; Salgado R; Zafeiroglou M; Pellegrini P; Venet D; Garaud S; Trinidad EM; Benítez S; Vuylsteke P; Polastro L; Wildiers H; Simon P; Lindeman G; Larsimont D; Van den Eynden G; Velghe C; Rothé F; Willard-Gallo K; Michiels S; Muñoz P; Walzer T; Planelles L; Penninger J; Azim HA; Loi S; Piccart M; Sotiriou C; González-Suárez E Nat Commun; 2020 Dec; 11(1):6335. PubMed ID: 33303745 [TBL] [Abstract][Full Text] [Related]
14. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895 [TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453 [TBL] [Abstract][Full Text] [Related]
16. RANKL Signaling and ErbB Receptors in Breast Carcinogenesis. Zoi I; Karamouzis MV; Adamopoulos C; Papavassiliou AG Trends Mol Med; 2016 Oct; 22(10):839-850. PubMed ID: 27567286 [TBL] [Abstract][Full Text] [Related]
17. RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Schramek D; Sigl V; Penninger JM Trends Endocrinol Metab; 2011 May; 22(5):188-94. PubMed ID: 21470874 [TBL] [Abstract][Full Text] [Related]
18. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334 [TBL] [Abstract][Full Text] [Related]
19. The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL. Simatou A; Sarantis P; Koustas E; Papavassiliou AG; Karamouzis MV Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066388 [TBL] [Abstract][Full Text] [Related]
20. The Roadmap of RANKL/RANK Pathway in Cancer. Casimiro S; Vilhais G; Gomes I; Costa L Cells; 2021 Aug; 10(8):. PubMed ID: 34440747 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]